The role of factor XIII in patient blood management.
Journal
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
ISSN: 1473-5733
Titre abrégé: Blood Coagul Fibrinolysis
Pays: England
ID NLM: 9102551
Informations de publication
Date de publication:
26 Sep 2024
26 Sep 2024
Historique:
received:
21
06
2024
accepted:
14
09
2024
medline:
14
10
2024
pubmed:
14
10
2024
entrez:
14
10
2024
Statut:
aheadofprint
Résumé
Factor XIII (FXIII), a plasma transglutaminase, is a coagulation factor that plays a crucial role in blood clotting and patient blood management. The studies have demonstrated that FXIII targets a wide range of additional substrates that have an important role in hemostasis, especially in posttraumatic patients, patients undergoing surgery or obstetrics, being involved in wound healing and tissue repair. Morover, FXIII deficiency has also been described and an extensive research has shown that FXIII deficiency is a rare coagulopathy that leads to longer bleeding time, perioperative and postoperative complications and slower wound healing. Present article aims to overview the diverse functions of FXIII and to highlight its role in patient blood management.
Identifiants
pubmed: 39397731
doi: 10.1097/MBC.0000000000001326
pii: 00001721-990000000-00168
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Franchini M, Marano G, Veropalumbo E, Masiello F, Pati I, Candura F, Profili S. Patient blood management: a revolutionary approach to transfusion medicine. Blood transfusion = Trasfusione del sangue. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6596379/ [Accessed 2 May 2023].
Muszbek L, Bereczky Z, Bagoly Z, Komáromi I, Katona É. Factor XIII: A Coagulation Factor With Multiple Plasmatic and Cellular Functions. Physiological Reviews 2011; 91:931–972.
Fabes J, Brunskill SJ, Curry N, Doree C, Stanworth SJ. Pro-coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia. Cochrane Database Syst Rev 2018; 12:CD010649.
Kleber C, Sablotzki A, Casu S, Olivieri M, Thoms KM, Horter J, et al. The impact of acquired coagulation factor XIII deficiency in traumatic bleeding and wound healing. Crit Care 2022; 26:69.
Alshehri FSM, Whyte CS, Mutch NJ. Factor XIII-A: an indispensable “Factor” in haemostasis and wound healing. Int J Mol Sci 2021; 22:3055.
Gupta S, Biswas A, Akhter MS, Krettler C, Reinhart C, Dodt J, et al. Revisiting the mechanism of coagulation factor XIII activation and regulation from a structure/functional perspective. Sci Rep 2016; 6:30105.
Dickneite G, Herwald H, Korte W, et al. Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions [Internet]. U.S. National Library of Medicine [cited 2 May 2023]. https://pubmed.ncbi.nlm.nih.gov/25652913/.
Strilchuk AW, Meixner SC, Leung J, Safikhan NS, Kulkarni JA, Russell HM, et al. Sustained depletion of FXIII-A by inducing acquired FXIII-B deficiency. Blood 2020; 136:2946–2954.
Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII deficiency. Semin Thromb Hemost 2009; 35:426–438.
Robert Breitkopf IW. FXIII deficiency occurs frequently in major trauma and influences transfusion requirements while levels of von Willebrand factor are well above thresholds [Internet]. Gavin Publishers; 2017 [cited 4 May 2023]. https://www.gavinpublishers.com/article/view/fxIII-deficiency-occurs-frequently-in-major-trauma-and-influences-transfusion-requirements-while-levels-of-von-willebrand-factor-are-well above-thresholds.
Tauber H, Innerhofer P, Breitkopf R, et al. Prevalence and impact of abnormal ROTEM(R) assays in severe blunt trauma: results of the ‘Diagnosis and Treatment of Trauma-Induced Coagulopathy (DIA-TRE-TIC) study’. Br J Anaesth 2011; 107: 378-387.
Kalbhenn J, Wittau N, Schmutz A, et al. Identification of acquired coagulation disorders and effects of target-controlled coagulation factor substitution on the incidence and severity of spontaneous intracranial bleeding during veno-venous ECMO therapy [Internet]. U.S. National Library of Medicine [cited 4 May 2023]. https://pubmed.ncbi.nlm.nih.gov/25823366/.
Amano S, Oka K, Sato Y, Sano C, Ohta R. Measuring factor XIII inhibitors in patients with factor XIII deficiency: a case report and systematic review of current practices in Japan. J Clin Med 2022; 11:1699.
Gerlach R, Raabe A, Zimmermann M, et al. Factor XIII deficiency and postoperative haemorrhage after neurosurgical procedures [Internet]. U.S. National Library of Medicine [cited 4 May 2023]. https://pubmed.ncbi.nlm.nih.gov/11118574 /.
Chan KYT, Yong ASM, Wang X, et al. The adhesion of clots in wounds contribute to hemostasis and can be enhanced by Coagulation Factor XIII [Internet]. U.S. National Library of Medicine [cited 4 May 2023]. https://pubmed.ncbi.nlm.nih.gov/33208779/.
Wettstein P, Haeberli A, Stutz M, Rohner M, Corbetta C, Gabi K, et al. Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding. Anesth Analg 2004; 99:1564–1569.
Korte WC, Szadkowski C, Gähler A, Gabi K, Kownacki E, Eder M, et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology 2009; 110:239–245.
Inbal A, Dardik R. Role of coagulation factor XIII (FXIII) in angiogenesis and tissue repair. Pathophysiol Haemost Thromb 2006; 35:162–165.
Richardson VR, Cordell P, Standeven KF, Carter AM. Substrates of Factor XIII-A: roles in thrombosis and wound healing. Clin Sci (Lond) 2013; 124:123–137.
Lechner C. Factor XIII (Fibrogammin P). Clinical experience in perioperative bleeding and wound healing – a case collection. CliniCum. The Magazine for Executives in Hospital. Wien: Medizin Medien Austria GmbH; 2011-2012. pp. 27-39.
Kleber C, Sablotzki A, Casu S, et al. The impact of acquired Coagulation Factor XIII deficiency in traumatic bleeding and wound healing [Internet]. U.S. National Library of Medicine [cited 6 May 2023]. https://pubmed.ncbi.nlm.nih.gov/35331308/.
Shi DY, Wang SJ. Advances of coagulation factor XIII. Chin Med J (Engl) 2017; 130:219–223.
Hayashi T, Kadohira Y, Morishita E, et al. A case of acquired FXIII deficiency with severe bleeding symptoms. Haemophilia 2012; 18:618–620.
Wozniak GH, Lutz H, Noll T, Alemany J. Behandlung stark sekretierender, chronischer Wunden mit Faktor XIII. II. Endothel und Faktor XIII. III.Klinische Modalitäten und Ergebnisse [Treatment of heavily secreting, chronic wounds with FXIII]. Z Wundheilung Heft 19, 10-19, Heft 20, 10-13 2001 6.
Alshehri FSM, Whyte CS, Mutch NJ. Factor XIII-A: an indispensable “factor” in haemostasis and wound healing [Internet]. U.S. National Library of Medicine; 2021 [cited 6 May 2023]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002558/.
Loof TG, Morgelin M, Johansson L, et al. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defence. Blood 2011; 118:2589–2598.
Burkhardt H, Zellner PR, Möller I. Factor XIII deficiency in burns. Chirurg 1977; 48:520–523.
Ichinose A. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control. Int J Hematol 2012 [cited 7 May 2023].
Whiting D, DiNardo JA. TEG and ROTEM: technology and clinical applications. Am J Hematol 2014; 89:228–232.
Amgalan A, Allen T, Othman M, Ahmadzia HK. Systematic review of viscoelastic testing (TEG/ROTEM) in obstetrics and recommendations from the women's SSC of the ISTH. J Thromb Haemost 2020; 18:1813–1838.
Raspé C, Besch M, Charitos EI, et al. Rotational thromboelastometry for assessing bleeding complications and factor XIII deficiency in cardiac surgery patients [Internet]. U.S. National Library of Medicine; 2018 [cited 27 June 2023]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714825/.
Gonzalez E, Moore EE, Moore HB. Management of trauma-induced coagulopathy with thrombelastography. Crit Care Clin 2017; 33:119–134.
Yan MTS, Rydz N, Goodyear D, Sholzberg M. Acquired factor XIII deficiency: a review. Transfus Apher Sci 2018; 57:724–730.
FXIII activity assays [Internet]. [cited 27 June 2023]. https://zedira.com/Blood-Coagulation/FXIII-Activity-Assays.
Lawrie AS, Green L, Mackie IJ, et al. Factor XIII--an under-diagnosed deficiency--are we using the right assays? [Internet]. U.S. National Library of Medicine [cited 23 May 2023]. https://pubmed.ncbi.nlm.nih.gov/20727071/.
Leitner M, Büchold C, Pasternack R, Binder NB, Moore GW. Clinical validation of an automated fluorogenic factor XIII activity assay based on isopeptidase activity. Int J Mol Sci 2021; 22:1002.
Kietaibl S, Ahmed A, Afshari A, Albaladejo P, Aldecoa C, Barauskas G, et al. Management of severe peri-operative bleeding: guidelines from the European Society of Anaesthesiology and Intensive Care: second update 2022. Eur J Anaesthesiol 2023; 40:226–304.
Factor XIII uses, side effects & warnings [Internet]. [cited 24 May 2023]. https://www.drugs.com/mtm/factor-xiii.html#warnings.
Abdel-Samad N. Treatment with recombinant factor XIII (Tretten) in a pregnant woman with factor XIII deficiency. Am J Case Rep 2017; 18:436–439.
Solomon C, Korte W, Fries D, Pendrak I, Joch C, Gröner A, et al. Safety of factor XIII concentrates analysis of more than 20 years of pharmacovigilance data [Internet]. U.S. National Library of Medicine; 2016 [cited 24 May 2023]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073543/.
DiGrande S. Biosimilars of haemophilia therapies: are they likely? [Internet]. Centre for Biosimilars; 2022 [cited 28 June 2023]. https://www.centerforbiosimilars.com/view/biosimilars-for-hemophilia-therapies-are-they-likely.
Mumford AD, Ackroyd S, Alikhan R, Bowles L, Chowdary P, Grainger J, et al. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors’ Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol 2014; 167:304–326.
Factor XIII dosage guide + max dose, adjustments [Internet]. [cited 24 May 2023]. https://www.drugs.com/dosage/factor-xiii.html.
Singh S, Akhter MS, Dodt J, Volkers P, Reuter A, Reinhart C, et al. Identification of potential novel interacting partners for coagulation factor XIII B (FXIII-B) subunit, a protein associated with a rare bleeding disorder. Int J Mol Sci 2019; 20:2682.